Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Nov:88:101199.
doi: 10.1016/j.resmer.2025.101199. Epub 2025 Aug 27.

Bronchiectasis in France: data on disease characteristics in 630 patients from the European Bronchiectasis registry (EMBARC)

Pierre-Régis Burgel  1 , Anne Bergeron  2 , Bernard Maitre  3 , Claire Andrejak  4 , Cristina Audoly  5 , Jean-François Boitiaux  6 , Boubou Camara  7 , Nathalie Coolen-Allou  8 , Benoit Douvry  9 , Gérard Chatté  10 , Annlyse Fanton  11 , Sylvie Leroy  12 , Clémence Martin  13 , Karine Michaux  14 , Annabelle Payet  15 , Hervé Pegliasco  16 , Frédéric Schlemmer  3 , Guillaume Vignal  17 , Agnès Duchange  18 , Espérie Burnet  19 , James D Chalmers  20 , Marlène Murris-Espin  21 ; EMBARC France and the GREPI, Groupe de Recherche et d'enseignement En Pneumo-Infectiologie - Société de Pneumologie de Langue Française (SPLF)
Affiliations
Free article
Multicenter Study

Bronchiectasis in France: data on disease characteristics in 630 patients from the European Bronchiectasis registry (EMBARC)

Pierre-Régis Burgel et al. Respir Med Res. 2025 Nov.
Free article

Abstract

Background: Little is known about the characteristics of adults with bronchiectasis in France.

Methods: A descriptive cross-sectional study was conducted to describe the characteristics of adults (≥18 years) with clinically-significant bronchiectasis, diagnosed on a combination of respiratory symptoms and CT scan findings, and followed in 18 participating centers. Data on, etiology, lung function, symptoms, microbiology, treatments and quality of life were collected.

Results: Between January 2016 and July 2022, 630 adults (females: 66 %; ≥55 years: 73.8 %) were included. Idiopathic and post-infective causes represented 33.0 % and 37.1 % respectively; COPD and asthma, which were present in 15.6 % and 23.6 % of subjects, were considered as causes of bronchiectasis in only 3.8 % and 2.9 %, respectively. Only 25 % had normal spirometry and 7.3 % required long-term oxygen therapy. Daily sputum production was present in 78.1 % and 29.0 % had a modified Medical Research Council (mMRC) dyspnea score ≥2. Positive bacterial sputum culture was found in 77.8 % of those with sputum samples (n = 455); including 157 (34.5 %) positive for Pseudomonas aeruginosa within the past year. During the year prior to study entry, 75.4 % of patients reported at least one respiratory exacerbation, 33.8 % had at least one hospitalization and 24.5 % received outpatient parenteral antimicrobial therapy (OPAT). Using the bronchiectasis severity index 26.0 %, 36.4 % and 37.6 % were considered as having mild, moderate and severe disease, respectively.

Conclusion: In France, adults with bronchiectasis experience significant disease burden. Respiratory exacerbations are responsible for healthcare utilization and their prevention may require specialized multidisciplinary care and the development of novel therapeutic interventions.

Keywords: Bronchiectasis; Pseudomonas aeruginosa; vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Marlene Murris Espin reports financial support was provided by Elivie. Marlene Murris Espin reports financial support was provided by SADIR Assistance. Bernard Maitre reports financial support was provided by Insmed Incorporated. Anne Bergeron reports financial support was provided by GREPI-SPLF. Burgel Pierre-Regis reports a relationship with Insmed Incorporated that includes: consulting or advisory. Burgel Pierre-Regis reports a relationship with Boehringer Ingelheim that includes:. Marlene Murris Espin reports a relationship with Insmed Incorporated that includes: consulting or advisory. Marlene Murris Espin reports a relationship with Zambon SpA that includes: consulting or advisory. James Chalmers reports a relationship with Insmed Incorporated that includes: consulting or advisory. James Chalmers reports a relationship with Griffols that includes: consulting or advisory. James Chalmers reports a relationship with Astra Zeneca that includes:. James Chalmers reports a relationship with Boehringer Ingelheim that includes: consulting or advisory. Bernard Maitre reports a relationship with Insmed Incorporated that includes: consulting or advisory. Clemence Martin reports a relationship with Insmed that includes: consulting or advisory. Clemence Martin reports a relationship with Astra Zeneca that includes: consulting or advisory. Clemence Martin reports a relationship with Zambon that includes: consulting or advisory. Pierre-Régis Burgel is Deputy Editor in Chief of Respiratory Medicine and Research. Given this role, he had no involvement in the peer review of this article and had no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to another journal editor. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

LinkOut - more resources